Mark J Cziraky

Summary

Affiliation: Health Outcomes Research
Country: USA

Publications

  1. ncbi request reprint Management of dyslipidemia in patients with metabolic syndrome
    Mark J Cziraky
    HealthCore Inc, 800 Delaware Avenue, Fifth Floor, Wilmington, Delaware 19801 1366 USA
    J Am Pharm Assoc (2003) 44:478-88; quiz 489-90. 2004
  2. pmc The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus
    Peter P Toth
    CGH Medical Center, 101 East Miller Rd, Sterling, IL, 61081, USA
    Cardiovasc Diabetol 11:109. 2012
  3. doi request reprint Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting
    Mark J Cziraky
    HealthCore, Inc, 800 Delaware Avenue, Wilmington, DE 19801, USA
    J Clin Lipidol 7:102-8. 2013
  4. pmc Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose?
    Marianne Ulcickas Yood
    EpiSource, LLC, Newton, MA, USA
    BMC Psychiatry 11:197. 2011
  5. ncbi request reprint The impact of residual CVD risk in the managed care setting
    Mark J Cziraky
    HealthCore, Inc, 800 Delaware Ave, Fifth Fl, Wilmington, DE 19801, USA
    Am J Manag Care 15:S74-80. 2009
  6. ncbi request reprint Statin safety: an assessment using an administrative claims database
    Mark J Cziraky
    HealthCore, Inc, Wilmington, Delaware 19801, USA
    Am J Cardiol 97:61C-68C. 2006
  7. ncbi request reprint NHBPEP: working to reduce death and disability from high blood pressure. National High Blood Pressure Education Program
    Mark J Cziraky
    Health Core, Newark, DE, USA
    J Am Pharm Assoc (Wash) 42:886-8. 2002
  8. ncbi request reprint Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed?
    Chaitanya A Sarawate
    Health Core, Inc, Wilmington, Delaware 19801, USA
    Clin Ther 29:196-209. 2007
  9. doi request reprint Attainment of combined optimal lipid values and the impact of lipid medication on cardiovascular outcomes and costs in a commercially insured population in the US
    Ralph A Quimbo
    HealthCore, Inc, Wilmington, DE 19801, USA
    J Med Econ 11:449-70. 2008
  10. ncbi request reprint Risk of cardiovascular events in patients at optimal values for combined lipid parameters
    Eric J Stanek
    Kos Pharmaceuticals, Inc, Cranbury, NJ, USA
    Curr Med Res Opin 23:553-63. 2007

Collaborators

Detail Information

Publications23

  1. ncbi request reprint Management of dyslipidemia in patients with metabolic syndrome
    Mark J Cziraky
    HealthCore Inc, 800 Delaware Avenue, Fifth Floor, Wilmington, Delaware 19801 1366 USA
    J Am Pharm Assoc (2003) 44:478-88; quiz 489-90. 2004
    ..To review the management of dyslipidemia in patients with metabolic syndrome...
  2. pmc The impact of serum lipids on risk for microangiopathy in patients with type 2 diabetes mellitus
    Peter P Toth
    CGH Medical Center, 101 East Miller Rd, Sterling, IL, 61081, USA
    Cardiovasc Diabetol 11:109. 2012
    ....
  3. doi request reprint Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting
    Mark J Cziraky
    HealthCore, Inc, 800 Delaware Avenue, Wilmington, DE 19801, USA
    J Clin Lipidol 7:102-8. 2013
    ..The occurrence of low rates of rhabdomyolysis among patients receiving lipid-lowering drugs (LLDs) in randomized clinical trials may be elucidated with population-based studies...
  4. pmc Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose?
    Marianne Ulcickas Yood
    EpiSource, LLC, Newton, MA, USA
    BMC Psychiatry 11:197. 2011
    ..The benefits of some second-generation antipsychotics (SGAs) must be weighed against the increased risk for diabetes mellitus. This study examines whether the association between SGAs and diabetes differs by dose...
  5. ncbi request reprint The impact of residual CVD risk in the managed care setting
    Mark J Cziraky
    HealthCore, Inc, 800 Delaware Ave, Fifth Fl, Wilmington, DE 19801, USA
    Am J Manag Care 15:S74-80. 2009
    ....
  6. ncbi request reprint Statin safety: an assessment using an administrative claims database
    Mark J Cziraky
    HealthCore, Inc, Wilmington, Delaware 19801, USA
    Am J Cardiol 97:61C-68C. 2006
    ..No hospitalized cases of the index AEs were observed in study subjects during the 6-month period before initiation of the lipid-lowering drug. Statin monotherapy as currently prescribed is generally well tolerated and safe...
  7. ncbi request reprint NHBPEP: working to reduce death and disability from high blood pressure. National High Blood Pressure Education Program
    Mark J Cziraky
    Health Core, Newark, DE, USA
    J Am Pharm Assoc (Wash) 42:886-8. 2002
  8. ncbi request reprint Achievement of optimal combined lipid values in a managed care setting: is a new treatment paradigm needed?
    Chaitanya A Sarawate
    Health Core, Inc, Wilmington, Delaware 19801, USA
    Clin Ther 29:196-209. 2007
    ..Published guidelines suggest the management of high-density lipoprotein cholesterol (HDL-C) and triglyceride (TG) values after the low-density lipoprotein cholesterol (LDL-C) goal is achieved...
  9. doi request reprint Attainment of combined optimal lipid values and the impact of lipid medication on cardiovascular outcomes and costs in a commercially insured population in the US
    Ralph A Quimbo
    HealthCore, Inc, Wilmington, DE 19801, USA
    J Med Econ 11:449-70. 2008
    ..To determine factors associated with the achievement of optimal lipid values (OLVs) and subsequent impact on clinical and economic outcomes...
  10. ncbi request reprint Risk of cardiovascular events in patients at optimal values for combined lipid parameters
    Eric J Stanek
    Kos Pharmaceuticals, Inc, Cranbury, NJ, USA
    Curr Med Res Opin 23:553-63. 2007
    ..The study objective was to evaluate the risk of CV events in patients attaining versus not attaining combined (LDL-C, HDL-C, and TG) optimal lipid values...
  11. doi request reprint Adherence to single-pill combination versus multiple-pill combination lipid-modifying therapy among patients with mixed dyslipidemia in a managed care population
    Siddhesh A Kamat
    HealthCore, Inc, Wilmington, DE, USA
    Curr Med Res Opin 27:961-8. 2011
    ..Single-pill combination (SPC) lipid-modifying therapies may improve patient adherence due to decreased pill burden and increased convenience for the patient...
  12. ncbi request reprint Clinical and economic outcomes of the Cincinnati Pharmacy Coaching Program for diabetes and hypertension
    Debra Wertz
    HealthCore, Wilmington, DE 19801, USA
    Manag Care 21:44-54. 2012
    ..The CPCP is a VBID implemented by Anthem Blue Cross & Blue Shield in Ohio. It provided tailored pharmacist-based educational services and financial incentives to participants...
  13. ncbi request reprint Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting
    Mark J Cziraky
    HealthCore Inc, Wilmington, Delaware, USA
    J Manag Care Pharm 14:S3-28; quiz S30-1. 2008
    ..However, clinical and epidemiologic data illustrate the need to expand the scope of therapies to reduce the residual cardiovascular risk associated with low HDL-C levels and elevated TG levels, even when LDL-C is managed successfully...
  14. doi request reprint Risk of cardiovascular events and all-cause mortality in patients treated with thiazolidinediones in a managed-care population
    Debra A Wertz
    HealthCore, Inc, 800 Delaware Ave, 5th Floor, Wilmington, DE 19801, USA
    Circ Cardiovasc Qual Outcomes 3:538-45. 2010
    ..This study directly compares risk of acute myocardial infarction (AMI), acute heart failure (AHF), or all-cause death among pioglitazone- and rosiglitazone-treated patients in a managed-care population...
  15. doi request reprint HER2 testing and subsequent trastuzumab treatment for breast cancer in a managed care environment
    John J Barron
    HealthCore, Inc, Wilmington, DE 19801, USA
    Oncologist 14:760-8. 2009
    ....
  16. doi request reprint Incidence of death and recurring acute coronary syndrome after stopping clopidogrel therapy in a large commercially-insured population in the US
    Judith J Stephenson
    HealthCore, Inc, Wilmington, DE 19801, USA
    Curr Med Res Opin 27:1079-87. 2011
    ..This study evaluated the risk of adverse outcomes (AOs), defined as death or recurrent ACS, after clopidogrel discontinuation in a managed-care population...
  17. doi request reprint Insomnia-related comorbidities and economic costs among a commercially insured population in the United States
    Michael Pollack
    AstraZeneca, Wilmington, DE, USA formerly HealthCore, Wilmington, DE 19801, USA
    Curr Med Res Opin 25:1901-11. 2009
    ..To describe the association between insomnia and comorbid conditions, and subsequent effects on total health costs and work productivity in a large managed-care setting...
  18. ncbi request reprint Effects of gemfibrozil conversion to fenofibrate on lipids in patients on statin therapy
    John C Corbelli
    Buffalo Cardiology and Pulmonary Associates, Williamsville, New York 14231, USA
    Am J Cardiol 90:1388-91. 2002
  19. ncbi request reprint Secondary prevention of acute coronary syndromes
    Janet H Dailey
    College of Pharmacy, University of Florida, Gainesville, USA
    J Am Pharm Assoc (2003) 44:S28-35; quiz S35-6. 2004
    ..To review the role of antithrombotic therapy for prevention of acute coronary syndrome (ACS) recurrence following hospital discharge...
  20. ncbi request reprint Antithrombotic therapy for acute coronary syndromes
    Sarah A Spinler
    Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, 600 South 43rd Street, Philadelphia, PA 19104, USA
    J Am Pharm Assoc (2003) 44:S14-26; quiz S26-7. 2004
    ..To review the role of antithrombotic therapy for treatment of acute coronary syndromes (ACS) in the hospital setting...
  21. ncbi request reprint Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting
    Lori Mosca
    Columbia University, New York, NY, USA
    Circulation 111:488-93. 2005
    ..This study evaluated optimal lipid-level attainment and treatment patterns on the basis of these guidelines in high-risk women in a managed care setting...
  22. ncbi request reprint Gender bias in lipid assessment and treatment following percutaneous coronary intervention
    Jennifer A Corbelli
    Buffalo Cardiology and Pulmonary Associates, 6460 Main St, Williamsville, NY 14231 9060, USA
    J Gend Specif Med 6:21-6. 2003
    ..To identify a possible gender bias in lipid assessment and treatment of patients following percutaneous coronary intervention (PCI)...
  23. ncbi request reprint National Pharmacy Cardiovascular Council treatment guidelines for the management of type 2 diabetes mellitus: toward better patient outcomes and new roles for pharmacists
    David Hawkins
    Southern School of Pharmacy, Mercer University, Atlanta, GA 30341, USA
    Pharmacotherapy 22:436-44. 2002